ThomasNet Home   |   Promote Your Business
Home  |   My ThomasNet News®  |   Industry Market Trends  |   Submit Release  |   Advertise  |   About Us May 24, 2012  

Australian Therapeutics Goods Administration Approval for ActiPatch Achieved

Print | 
Email |  Comment   Share  

(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)

BioElectronics Corporation
4539 Metropolitan Ct.
Frederick,, MD, 21704
USA



Press release date: October 9, 2007

FREDERICK, Md., Oct. 9 - BioElectronics Corporation, (Pink Sheets: BIEL), announced today that the Australian Therapeutic Goods Administration has cleared ActiPatch for sale by its distributor, Endotherapeutics Party Limited.

"We are confident that the experienced sales professionals of Endotherapeutics will successfully launch ActiPatch in the Australian market. Endotherapeutics' team has many decades of experience in the medical devices market and their people come from well known established medical devices companies," said Andrew Whelan, President of BioElectronics Corporation.

Ivan Srejber, Managing Director of Endotherapeutics Party Limited, said "We have extensive experience in launching products and establishing significant market share for previously unknown products. We are very excited about the market potential for ActiPatch in Australia and look forward to a mutually beneficial business partnership with BioElectronics Corporation."

About Endotherapeutics Party Limited:

Founded in 1998, Endotherapeutics has provided medical technologies for the health care specialist throughout Australia. Companies represented by Endotherapeutics are leaders in their specific market segments. To learn more about Endotherapeutics Party Limited please visit http://www.endotherapeutics.com.au/.

About BioElectronics:

BioElectronics Corporation is the maker of ActiPatch. ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.

For more information visit http://www.bioelectronicscorp.com/

Source: BioElectronics Corporation

CONTACT: Andrew J. Whelan, President & CEO of BioElectronics Corporation, +1-866-757-2284, Fax: +1-301-874-6935, info@actipatch.net

Web site: http://www.bioelectronicscorp.com/ http://www.endotherapeutics.com.au/
Print | 
Email |  Comment   Share  
Contacts: View detailed contact information.


 

Post a comment about this story

Name:
E-mail:
(your e-mail address will not be posted)
Comment title:
Comment:
To submit comment, enter the security code shown below and press 'Post Comment'.
 



 See related product stories
Don’t hunt for stories like this.
Let Health, Medical and Dental Supplies & Equipment
Product News Come to You!
Get a Free Subscription
to Product News Alerts.
Start Your Free
Subscription to
Industry Market Trends.
 See more product news in:
Health, Medical and Dental Supplies and Equipment
 More New Product News from this company:
Anti-Inflammatory Patch eases heel pain.
Mask ensures proper placement of ActiPatch Therapy over eyes.
More ....
 Other News from this company:
BioElectronics Announces Expansion of Italian Market
More ....
 Tools for you
Watch Company 
View Company Profile
Company web site
More news from this company
E-Mail Story
Save Story
Search for suppliers of
Patches


Home  |  My ThomasNet News®  |  Industry Market Trends  |  Submit Release  |  Advertise  |  Contact News  |  About Us
Brought to you by Thomasnet.com        Browse ThomasNet Directory

Copyright © 2012 Thomas Publishing Company
Terms of Use - Privacy Policy



Error close

Please enter a valid email address